unique grouping of companies presently
serving the varied needs of the health care industry. Through its
nutraceutical business, the Company creates, develops, manufactures
and markets products worldwide. The Company's biotechnology
business uses its patented plant-based technology to produce
vaccines and therapeutic antibodies. Its pharmaceutical business
operates a cGMP facility for the production and sale of Paclitaxel
and related drugs and provides technical services through its
contract research organization. Further information is available at
www.iBioPharma.com.
Statements included in this release related to Integrated
BioPharma, Inc. may constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties
such as competitive factors, technological development, market
demand, and the company's ability to obtain new contracts and
accurately estimate net revenues due to variability in size, scope
and duration of projects, and internal issues in the sponsoring
client. Further information on potential risk factors that could
affect the company's financial results can be found in the
company's Reports filed with the Securities and Exchange
Commission.
CONTACT: Jeffery Leach, VP, or Dina Masi, CFO, , bothof
Integrated BioPharma Inc., +1-888-319-6962 d.masi@ibiopharma.com
Web site: http://www.iBioPharma.com/
Ticker Symbol: (NASDAQ-NMS:INBP)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
'"/>Page: 1 2 Related medicine technology :1.
Integrated BioPharmas Proprietary Vaccine Technology Achieves
Strong Positive Results2.
Pieris Progresses Proprietary Asthma Program: Validation of
Pulmonary Delivery of Anticalin-Based Protein Product Candidate3.
Neurogen Announces Positive Results for Proprietary Insomnia Drug
in Two Chronic Insomnia Clinical Trials4.
Pieris Progresses Development of its Proprietary Biotherapeutics
Platform: Successful Demonstration of Dual Targeting With
Duocalin(R) Technology5.
Modigene Announces Successful Completion of Pharmacokinetic &
Pharmacodynamic Pre-Clinical Experiments for Proprietary
Long-Acting Human Growth Hormone, Long-acting Interferon Beta and
Long-acting Erythropoietin6.
Neurogen Proprietary Insomnia Compound Data for Two Studies
Presented at Associated Professional Sleep Societies Annual Meeting7.
Neurogen Proprietary Insomnia Compound Data Presented at Associated
Professional Sleep Societies Annual Meeting8.
Neurogen Proprietary Insomnia Compound Data Presented at American
Psychiatric Association Annual Meeting9.
Cytogen Reports Publication Validating the Utility of its
Proprietary ProChart Database10.
Seattle Genetics Highlights Data on its Proprietary Antibody-Drug
Conjugate Technology at AACR11.
Helix BioMedix to Discuss Potential of Its Proprietary Peptides at
the BIO International Convention